Search Results - "Travis, Patrick M"

Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial by Sharman, Jeff P, Brander, Danielle M, Mato, Anthony R, Ghosh, Nilanjan, Schuster, Stephen J, Kambhampati, Suman, Burke, John M, Lansigan, Frederick, Schreeder, Marshall T, Lunin, Scott D, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M, Chandler, Jason C, Kolibaba, Kathryn S, Sportelli, Peter, Miskin, Hari P, Weiss, Michael S, Flinn, Ian W

“…Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this…”
Get full text

Electronic patient-reported outcomes in a cohort of patients with lung cancer treated in the community with shorter versus longer course PD1/PDL1 therapy by Kolodziej, Michael A., Kwiatkowsky, Lavi, Travis, Patrick M., Blau, Sibel, Kuthiala, Sejal, Telivala, Bijoy Pankaj, Calkins, Geoffrey, Parrinello, Christina

“…e18810 Background: PD1/PDL1 (IO) therapy has been extensively studied as monotherapy and in combination with other IO therapy, chemotherapy and targeted…”
Get full text

Oncolytic virus CF33-hNIS monotherapy for the treatment of gastrointestinal (GI) malignancies by Li, Daneng, Shields, Anthony F., Mamdani, Hirva, Leddon, Jennifer, Travis, Patrick M., Egelston, Colt A., Colunga Flores, Oscar, Hamilton, Stanley R., Austria, Janet, Seiz, Amanda, Yavrom, Sharon, Byon, John Chong Han, Woodard, Paul Paul, Wilkinson, Grey A

“…749 Background: CF33-hNIS is a novel chimeric DNA vaccinia virus engineered with the human sodium-iodide symporter (hNIS) gene. CF33-hNIS selectively…”
Get full text

Study Assessing the All4Cure Health Technology Intervention on Patient Activation in Multiple Myeloma by Moezi, Mehdi M., Kanaan, Mohamad, Travis, Patrick M., Graff, Tara, Zheng, Cheng, Dunivan, Jessa, Wood, Tiffany, Essiet, Sophia, Faucheaux, Jessica, Decker, Brian, Wren, Jennifer, Chhun, Leena, Piboonvaranggoon, Jayne, Walker, Mark, Buckingham, Trudy, Guidi, Joseph, Altimari, Shannon, Blau, C. Anthony

“…BACKGROUND Over the past 2 decades, outcomes have improved markedly in patients with multiple myeloma, a result attributable to the development of highly…”
Get full text

Effect of adding ublituximab to ibrutinib on PFS, ORR, and MRD negativity in previously treated high-risk chronic lymphocytic leukemia: Final results of the GENUINE phase III study by Sharman, Jeff P., Brander, Danielle M., Mato, Anthony R., Ghosh, Nilanjan, Schuster, Stephen J., Kambhampati, Suman, Burke, John M., Lansigan, Frederick, Schreeder, Marshall T., Lunin, Scott D, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M., Chandler, Jason Claud, Kolibaba, Kathryn S., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Flinn, Ian

“…Abstract only 8022 Background: The BTK inhibitor ibrutinib (IB) has advanced the treatment for patients (pts) with CLL, however, among pts with high-risk CLL,…”
Get full text

Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study by Sharman, Jeff Porter, Brander, Danielle M., Mato, Anthony R., Kambhampati, Suman, Burke, John M., Lansigan, Frederick, Schreeder, Marshall T., Lunin, Scott D., Ghosh, Nilanjan, Zweibach, Alexander, Shtivelband, Mikhail, Travis, Patrick M., Chandler, Jason Claud, Kolibaba, Kathryn S., Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Flinn, Ian

“…Abstract only 7504 Background: Patients (pts) with high-risk chronic lymphocytic leukemia (CLL) defined by interruptions in TP53 (either by mutation or…”
Get full text

Mode of chemotherapy does not affect complications with an implantable venous access device by Brown, Danielle F., Muirhead, Michael J., Travis, Patrick M., Vire, Sharon R., Weller, JoAnn, Hauer‐Jensen, Martin

“…BACKGROUND Few reports have been made regarding the long term safety of implantable venous access devices used for the delivery of chemotherapeutic agents. The…”
Get full text